Replicate Study design for Brazil [Regulatives / Guidelines]

posted by Weidson – Brazil, 2018-05-22 22:51 (2162 d 18:12 ago) – Posting: # 18799
Views: 2,269

Dear balakotu

The ANVISA have adopted the EMA's Approach. However, for you use this approach you need to convince them that their drug is highly variable. I hope I have helped you.


Best Regards
Weidson C. de Souza


Edit: Post moved. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,991 posts in 4,827 threads, 1,647 registered users;
75 visitors (1 registered, 74 guests [including 9 identified bots]).
Forum time: 17:04 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5